Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
83 hedge funds and large institutions have $175M invested in Adamas Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 20 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 89 → 83 (-6)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
35% less capital invested
Capital invested by funds: $268M → $175M (-$93.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.68M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.32M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.98M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.75M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$9.44M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.86M |
| 3 |
CPH
C Partners Holding
Zurich,
Switzerland
|
-$3.69M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$1.42M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.22M |
ADMS Hedge Fund Activity: Q3 2015 in Review
83 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2015, worth a combined $175M — down 35% from $268M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ADMS and 14 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 34 added.
The largest buyer was Great Point Partners, adding an estimated $7.68M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $9.44M sold.
- 83 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2015, down from 89 in Q2 2015.
- Funds reported $175M of Adamas Pharmaceuticals stock for Q3 2015, down 35% quarter-over-quarter.
- 14 funds opened new Adamas Pharmaceuticals positions in Q3 2015 and 20 closed out, a net change of -6 holders.
- The largest Adamas Pharmaceuticals buyer in Q3 2015 was Great Point Partners, an estimated $7.68M added.
- The largest Adamas Pharmaceuticals seller in Q3 2015 was EverPoint Asset Management, an estimated $9.44M sold.
Based on aggregated 13F filings for Q3 2015.